Gilead Sciences, Inc. (NASDAQ:GILD) Stock Position Raised by Kestra Investment Management LLC

Kestra Investment Management LLC lifted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 51.1% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,789 shares of the biopharmaceutical company’s stock after purchasing an additional 1,281 shares during the period. Kestra Investment Management LLC’s holdings in Gilead Sciences were worth $350,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the stock. AMF Tjanstepension AB lifted its position in shares of Gilead Sciences by 14.7% in the 3rd quarter. AMF Tjanstepension AB now owns 400,819 shares of the biopharmaceutical company’s stock valued at $33,645,000 after acquiring an additional 51,390 shares in the last quarter. Swedbank AB lifted its holdings in shares of Gilead Sciences by 10.2% in the third quarter. Swedbank AB now owns 2,047,609 shares of the biopharmaceutical company’s stock valued at $171,672,000 after purchasing an additional 189,622 shares in the last quarter. nVerses Capital LLC acquired a new stake in shares of Gilead Sciences in the third quarter worth $25,000. Foundations Investment Advisors LLC grew its holdings in shares of Gilead Sciences by 21.1% during the third quarter. Foundations Investment Advisors LLC now owns 49,665 shares of the biopharmaceutical company’s stock valued at $4,164,000 after buying an additional 8,662 shares in the last quarter. Finally, Signaturefd LLC raised its position in Gilead Sciences by 12.1% during the third quarter. Signaturefd LLC now owns 21,000 shares of the biopharmaceutical company’s stock valued at $1,761,000 after buying an additional 2,271 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $107.65 on Thursday. The company has a market cap of $134.16 billion, a price-to-earnings ratio of 290.95, a PEG ratio of 0.87 and a beta of 0.18. The business has a 50 day moving average price of $94.70 and a 200 day moving average price of $88.23. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $107.81.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. Research analysts predict that Gilead Sciences, Inc. will post 7.94 earnings per share for the current year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Stockholders of record on Friday, March 14th will be issued a dividend of $0.79 per share. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date is Friday, March 14th. This represents a $3.16 annualized dividend and a dividend yield of 2.94%. Gilead Sciences’s payout ratio is presently 832.43%.

Insider Activity

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 248,645 shares of the firm’s stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $92.76, for a total value of $23,064,310.20. Following the completion of the sale, the chief financial officer now owns 138,919 shares in the company, valued at approximately $12,886,126.44. This trade represents a 64.16 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Merdad Parsey sold 164,211 shares of the business’s stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total value of $15,094,275.12. Following the sale, the insider now owns 80,801 shares in the company, valued at approximately $7,427,227.92. This represents a 67.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 713,000 shares of company stock valued at $67,945,181. Insiders own 0.29% of the company’s stock.

Analyst Ratings Changes

GILD has been the subject of a number of research reports. Morgan Stanley raised their price objective on Gilead Sciences from $113.00 to $123.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 12th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $80.00 price objective on shares of Gilead Sciences in a research report on Wednesday, December 11th. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research report on Wednesday, February 12th. Citigroup initiated coverage on shares of Gilead Sciences in a report on Thursday, November 14th. They set a “buy” rating and a $125.00 price target on the stock. Finally, Maxim Group lowered Gilead Sciences from a “buy” rating to a “hold” rating in a report on Friday, November 8th. Eleven investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $102.08.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.